10.6 Erectile Dysfunction, Low Desire and Gynaecomastia
Key Takeaways
Assess sexual desire, erectile function, cardiovascular risk and medicine effects together.
Check nitrate, nitric oxide donor and riociguat use and cardiovascular safety before offering sildenafil.
Differentiate central glandular enlargement from a suspicious breast lesion. Investigate unexplained adult gynaecomastia.
Separate erectile function from sexual desire
Ask privately what changed and what the patient would like help with. In erectile dysfunction, clarify the onset, situations in which the difficulty occurs, morning erections, rigidity and duration. Ask separately about desire, arousal, ejaculation, pain, mood, relationship issues and performance concerns. Preserved morning erections and a situational pattern may suggest a psychological contribution, but assess other risk factors too. Low desire can reflect depression, psychosocial context, a medicine or endocrine disease. Erectile dysfunction and low desire can occur together. Ask about cardiovascular symptoms and exercise tolerance and review diabetes, smoking, blood pressure, alcohol, surgery, neuropathy and medicines. Some antidepressants and hormonal treatments can affect sexual function. Arrange a prescriber review before changing treatment. Consider assessing psychological or relationship factors and offering psychosexual support when appropriate.
Measure blood pressure and assess vascular, neurological, genital or endocrine findings as indicated with appropriate explanation, consent and chaperoning. The EAU 2026 basic male assessment includes glucose or HbA1c and lipids if not recently assessed, plus fasting early-morning total testosterone. With suspected hypogonadism, confirm a low testosterone result on a separate morning using an appropriate assay and interpret it against symptoms. LH, selected FSH and prolactin can help distinguish testicular from central contributors where indicated. A low testosterone reading during acute illness or a single non-morning value cannot establish chronic hypogonadism. New visual symptoms, headache or a suggestive pituitary hormone pattern can require specialist assessment. Exogenous testosterone can suppress spermatogenesis; discuss fertility before treatment.
Check cardiovascular safety before offering a PDE5 inhibitor
- Assess cardiovascular risk. Ask whether exertional symptoms require review before sexual activity. Defer initiation and seek appropriate cardiac assessment for unstable cardiovascular symptoms. If treatment is suitable, explain how to use the chosen preparation and review interactions.
- Check current medicines and substances. Sildenafil is contraindicated with nitrates in any form, including as-needed glyceryl trinitrate, with nitric-oxide donors such as amyl nitrite, and with riociguat. Do not ask a patient to stop anti-anginal treatment temporarily to take sildenafil. Discuss non-PDE5 options with the treating team, for example a vacuum device or other specialist treatment.
- Explain what to do about chest pain. Seek urgent help and tell the emergency team when any PDE5 inhibitor was taken before a nitrate is considered.
HSE erectile dysfunction information · EAU 2026 erectile dysfunction · EAU male hypogonadism · HPRA sildenafil product information.
A man with diabetes and stable angina requests sildenafil for persistent erectile dysfunction. He regularly uses prescribed glyceryl trinitrate spray for exertional symptoms. What is the appropriate initial decision?
Start low-dose sildenafil and retain as-needed nitrate use
Defer sildenafil and review cardiac status and suitable erectile dysfunction options because nitrate co-use is contraindicated
Advise using sildenafil and glyceryl trinitrate together to reduce dizziness
Start testosterone on the basis of erectile symptoms alone
Distinguish glandular breast tissue from a suspicious lesion
Gynaecomastia is enlargement of male breast glandular tissue, usually felt centrally beneath the areola. Fatty enlargement may be more diffuse. A hard, irregular or eccentric lesion, fixation, new nipple retraction, bloody discharge or suspicious nodes warrants prompt diagnostic assessment through the local breast pathway. Gynaecomastia can be tender, particularly when recent; tenderness or use of a medicine associated with gynaecomastia cannot rule out a coincident suspicious lesion. Unexplained new breast enlargement in an adult warrants assessment for its cause rather than assuming physiological change.
Ask about onset and progression, pubertal stage or fertility and sexual symptoms, medicines such as spironolactone or antiandrogens, anabolic steroid use, and features of liver, renal or thyroid disease. Examine both breasts and, when appropriate and with consent, examine the testes and assess signs of under-virilisation or systemic disease. For unexplained or atypical presentations use the history, examination and specialist pathway to select endocrine or organ-function tests. The 2026 SIAMS guideline includes LH, fasting morning testosterone, SHBG, albumin, prolactin and β-hCG in its named work-up when further assessment is needed. Review liver, renal or thyroid tests in context. Low testosterone with elevated LH suggests a testicular cause, while a raised β-hCG can warrant evaluation for a secreting tumour. The evaluation of an eccentric hard mass proceeds through the breast pathway even if a hormone or medicine could contribute to general glandular enlargement. Breast imaging and sampling are determined by the specialist findings. Examine a testicular lump or suspected tumour promptly under the relevant pathway. Clear physiological pubertal change in an otherwise well adolescent can often be followed with review. Address a reversible contributor in conjunction with the prescriber. Persistent, progressive or distressing enlargement merits reassessment or referral.
EAA gynaecomastia guideline · SIAMS 2026 clinical practice guideline · Irish NCCP breast referral resources.
A 67-year-old taking spironolactone reports a new breast lump. Examination identifies a hard lesion eccentric to the nipple with new nipple retraction. What is the best next step?
Reassure because spironolactone fully explains any breast finding
Wait until the contralateral breast develops a similar lump
Arrange prompt assessment through the local symptomatic breast pathway
Prescribe testosterone without further examination
Sections you finish are checked off in the contents.